Equillium Will Study In-Licensed Itolizumab In Three Indications In 2019

 
• By Mandy Jackson
  
Emerging Company Profile Regular column feature image Version 2
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business